Development and Systematic Evaluation of a Low-Irritation PFD-AIS Formulation for Pulmonary-Targeted Therapy
Open Access
- 23 January 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 197
Abstract
Background: To overcome the gastrointestinal and hepatic toxicity of oral pirfenidone (PFD) in the treatment of idiopathic pulmonary fibrosis (IPF), this study systematically constructed a minimal-component, buffer-free pirfenidone aerosol inhalation solution (PFD-AIS), achieving lung-targeted delivery, reduced systemic exposure, and maintained antifibrotic efficacy. Methods: Analytical methods for PFD-AIS, covering content, related substances, aerodynamic particle size distribution (APSD), and delivered dose uniformity, were established. The prescription and preparation process of the formulation was optimized by evaluating its key quality attributes. Pharmacodynamic and pharmacokinetic evaluations of PFD-AIS were performed in a mouse lung-fibrosis model and SD rats. Results: The final specification of PFD-AIS was set to 40 mg:4 mL, containing 40 mg of PFD, 28 mg of sodium chloride, and 4 mL of injection water with a preparation process of 40 °C for 60 min and a pH range of 4–8. The PFD-AIS exhibited a fine particle fraction (FPF) of 56.1%, meeting the requirements for deep lung deposition. The delivered dose and delivery rate were 17.52 mg and 2.48 mg/min, respectively, both complying with inhalation formulation standards. In the bleomycin-induced IPF mouse model, the PFD-AIS markedly improved pulmonary fibrosis pathology, reduced the lung coefficient, and significantly lowered serum ALT/AST levels, indicating hepatic protection. In the SD rats, compared with oral dosing, PFD-AIS administration resulted in significantly lower AUC0−t (−63%) and AUC0–∞ (−67%) values, demonstrating a substantial reduction in systemic drug exposure. Conclusion: This work presents a complete, systematic chain—from formulation, process, and quality control to pharmacodynamics and pharmacokinetics—of a PFD-AIS. The PFD-AIS is effective and feasible, featuring a stable preparation process and controllable quality. Lung-directed drug delivery enhances PFD’s therapeutic efficacy, reduces systemic exposure and liver toxicity, and offers significant clinical advantages.Keywords
Funding Information
- Science and Technology Research Project of Jilin Province Department of Education (JJKH20240702CY)
This publication has 56 references indexed in Scilit:
- Preparation and comprehensive preclinical study of Peramivir inhalation solution: Achieving accurate drug deliveryBiomedicine & Pharmacotherapy, 2025
- Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary FibrosisChest, 2025
- Redox-activatable inhalable mucoadhesive proteinic nanotherapeutics for targeted treatment of lung cancerBiomaterials, 2024
- siTGF-β1 and pirfenidone contained Ionizable-Liposomal nanodrug for enhanced treatment of Idiopathic pulmonary fibrosisChemical Engineering Journal, 2024
- Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblastsActa Biomaterialia, 2024
- Mucus Transpiration as the Basis for Chronic Cough and Cough HypersensitivityLung, 2023
- SIRT6 Protects Against Lipopolysaccharide-Induced Inflammation in Human Pulmonary Lung Microvascular Endothelial CellsInflammation, 2023
- Multicenter Population Pharmacokinetics and Exposure–Efficacy Analysis of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisClinical Pharmacokinetics, 2023
- Alveolar Epithelial Type 2 Cell Dysfunction in Idiopathic Pulmonary FibrosisLung, 2022
- Experimental Estimation of Membrane Tension Induced by Osmotic PressureBiophysical Journal, 2016